AXIM Biotechnologies, Inc. (AXIM)

USD 0.0

(11.11%)

Market Cap (In USD)

1.2 Million

Revenue (In USD)

39.51 Thousand

Net Income (In USD)

-8.05 Million

Avg. Volume

361.38 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.001-0.021
PE
-0.2
EPS
-0.02
Beta Value
1.114
ISIN
US05463V1008
CUSIP
05463V100
CIK
1514946
Shares
301959000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John W. Huemoeller II
Employee Count
-
Website
https://www.aximbiotech.com
Ipo Date
2014-09-02
Details
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.